# US 2019/0315870 A1 · Antibodies against mica and/or micb and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315870 A1
- Document ID: US20190315870A1
- Status: Published application
- Kind: A1
- Application number: 16/362,411
- Filed: 2019-03-22
- Published: 2019-10-17
- Earliest claimed: 2018-03-23
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Michelle Renee KUHNE; Alan J. KORMAN; Haichun HUANG; Yiming YIN; Robert F. GRAZIANO; Natalie A. BEZMAN; Pavel STROP; Richard Y. HUANG; Guodong CHEN; Mohan SRINIVASAN; Peter Sung Keun LEE; Gamze Ozlem CAMDERE
- Web page: https://patentgrep.com/patent/US20190315870A1

## CPC

- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- A61P 35/00: Antineoplastic agents
- C12N 15/85: for animal cells
- A61K 2039/505: {comprising antibodies}
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.

## Claims

### Claim 1

An antibody that specifically binds to human MHC class I polypeptide-related sequence A (MICA) and/or human MEW class I polypeptide-related sequence B (MICB), comprising a heavy chain variable region (VH) and a light chain variable region (VL); wherein the VH comprises a VH complementarity determining region (CDR) 1, a VH-CDR2, and a VH-CDR3 and the VL comprises a VL-CDR1, a VL-CDR2, and a VL-CDR3; wherein the VH-CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 7, 17, 27, 37, and 47.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein:
(a) the VH-CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 16, 26, 36, and 46;
(b) the VH-CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 15, 25, 35, and 45;
(c) the VL-CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 18, 28, 38, and 48;
(d) the VL-CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 9, 19, 29, 39, and 49;
(e) the VL-CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 20, 30, 40, and 50; or
any combination of (a)-(e).

### Claim at position 3

3-6. (canceled)

### Claim 7 (depends on 1)

The antibody of claim 1, wherein
(a) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:5, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:6, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:7, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:8, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:9, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:10;
(b) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:15, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:16, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:17, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:18, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:19, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:20;
(c) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:25, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:26, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:27, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:28, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:29, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:30;
(d) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:35, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:36, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:37, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:38, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:39, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:40; or
(e) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:45, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:46, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:47, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:48, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:49, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:50.

### Claim 8 (depends on 1)

The antibody of claim 1, wherein the antibody has one or more properties selected from the group consisting of:
(a) the antibody inhibits shedding of MICA by a tumor cell;
(b) the antibody increases membrane bound MICA on a tumor cell;
(c) the antibody reduces soluble MICA level in the serum in a patient;
(d) the antibody mediates enhanced ADCC and/or ADCP;
(e) the antibody mediates enhanced antigen processing and/or cross-presentation by a cell;
(f) the antibody inhibits tumor growth and/or metastasis;
(g) the antibody reduces tumor volume;
(h) the antibody increases progression-free survival;
(i) the antibody increases overall survival; and
(j) any combination thereof.

### Claim 9 (depends on 1)

The antibody of any one of claim 1, wherein:
(a) the VH comprises an amino acid sequence having at least about 70% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 12, 22, 32, and 42;
(b) the VL comprises an amino acid sequence having at least about 70% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 14, 24, 34, and 44; or
(c) both (a) and (b).

### Claim at position 7

10-12. (canceled)

### Claim 13 (depends on 1)

The antibody of claim 1, wherein
(a) the VH comprises the amino acid sequence set forth in SEQ ID NO:2 and the VL comprises the amino acid sequence set forth in SEQ ID NO:4;
(b) the VH comprises the amino acid sequence set forth in SEQ ID NO:12 and the VL comprises the amino acid sequence set forth in SEQ ID NO:14;
(c) the VH comprises the amino acid sequence set forth in SEQ ID NO:22 and the VL comprises the amino acid sequence set forth in SEQ ID NO:24;
(d) the VH comprises the amino acid sequence set forth in SEQ ID NO:32 and the VL comprises the amino acid sequence set forth in SEQ ID NO:34; or
(e) the VH comprises the amino acid sequence set forth in SEQ ID NO:42 and the VL comprises the amino acid sequence set forth in SEQ ID NO:44.

### Claim 14 (depends on 1)

The antibody of claim 1, wherein:
(a) the antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:58, and a light chain comprising the amino acid sequence set forth in SEQ ID NO:60;
(b) the antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:130, and a light chain comprising the amino acid sequence set forth in SEQ ID NO:60;
(c) the antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:62, and a light chain comprising the amino acid sequence set forth in SEQ ID NO:64;
(d) the antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:66, and a light chain comprising the amino acid sequence set forth in SEQ ID NO:68; or
(e) the antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:70, and a light chain comprising the amino acid sequence set forth in SEQ ID NO:72.

### Claim 15 (depends on 1)

The antibody of claim 1, wherein the antibody binds an epitope on human MICA, wherein the epitope comprises:
(a) one or more amino acid residues of human MICA selected from the group consisting of G254, D255, L257, Y264, W267, and any combination thereof corresponding to SEQ ID NO: 51, as determined by yeast surface display;
(b) amino acid residues G254, D255, L257, Y264, and W267 corresponding to SEQ ID NO: 51, as determined by yeast surface display
(c) amino acid residues W150-M163 corresponding to SEQ ID NO: 51, as determined by hydrogen/deuterium exchange mass spectrometry (HDX-MS);
(d) amino acid residues Y231-T238 corresponding to SEQ ID NO: 51, as determined by hydrogen/deuterium exchange mass spectrometry (HDX-MS);
(e) amino acid residues D255-Q265 corresponding to SEQ ID NO: 51, as determined by hydrogen/deuterium exchange mass spectrometry (HDX-MS)
(f) amino acid residues W253-W267 corresponding to SEQ ID NO: 51, as determined by hydrogen/deuterium exchange mass spectrometry (HDX-MS);
(g) amino acid residues L201-N220 corresponding to SEQ ID NO:51, as determined by hydrogen/deuterium exchange mass spectrometry (HDX-MS);
(h) amino acid residues T238-Q252 corresponding to SEQ ID NO:51, as determined by hydrogen/deuterium exchange mass spectrometry (HDX-MS);
(i) amino acid residues L201-N220 and T238-Q252 corresponding to SEQ ID NO:51, as determined by hydrogen/deuterium exchange mass spectrometry (HDX-MS);
(j) amino acid residues 8240, Q241, D242, V244, and 8279 corresponding to SEQ ID NO:51, as determined by yeast surface display;
(j) amino acid residues P258, G260, G262, and Y264 corresponding to SEQ ID NO:51, as determined by yeast surface display; or
(k) any combination thereof.

### Claim at position 11

16-29. (canceled)

### Claim 30 (depends on 1)

The antibody of claim 1, wherein the antibody specifically binds human MICA with:
(a) a KD of about 1×10−4 M M or less, wherein KD is measured by surface plasmon resonance (Biacore) analysis;
(b) an on rate (kon) of about 1×10−4 M 1/Ms or more, wherein the kon rate is measured by surface plasmon resonance (Biacore) analysis;
(c) an off rate (koff) of about 1×10−4 M l/s or less, wherein the koff is measured by surface plasmon resonance (Biacore) analysis; or
(d) any combination of (a)-(c).

### Claim at position 13

31-32. (canceled)

### Claim 33 (depends on 1)

The antibody of claim 1, wherein the antibody is selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4 or a variant thereof.

### Claim 34

(canceled)

### Claim 35 (depends on 1)

The antibody of claim 1, which is non-fucosylated or hypo-fucosylated.

### Claim 36 (depends on 1)

The antibody of claim 1, wherein the antibody comprises a constant region in the heavy chain, and wherein the constant region comprises a G to A mutation at a position that corresponds to residue 234 in SEQ ID NO: 58.

### Claim 37 (depends on 1)

The antibody of claim 1, wherein the antibody is a human antibody, a humanized antibody, or a chimeric antibody.

### Claim at position 19

38-47. (canceled)

### Claim 48 (depends on 1)

A polynucleotide or a set of polynucleotides encoding the antibody of claim 1.

### Claim 49 (depends on 48)

A vector or a set of vectors comprising the polynucleotide or the set of polynucleotides of claim 48.

### Claim 50 (depends on 48)

A host cell comprising the polynucleotide or the set of polynucleotides of claim 48.

### Claim 51 (depends on 1)

An immunoconjugate comprising the antibody of claim 1 and a therapeutic agent.

### Claim at position 24

52-55. (canceled)

### Claim 55 (depends on 1)

A pharmaceutical composition comprising the antibody of claim 1.

### Claim at position 26

56-71. (canceled)

### Claim 72 (depends on 1)

A method of treating a cancer in a subject in need thereof, comprising administering to the subject the antibody of claim 1.

### Claim at position 28

73-107. (canceled)

### Claim 108 (depends on 48)

A method of preparing an antibody comprising expressing the polynucleotide or the set of polynucleotides of claim 48 in a host cell under suitable conditions.

### Claim 109

(canceled)
